Literature DB >> 1396750

Characterization of cell-bound papain-soluble beta-lactamases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens.

I Eliasson1, C Kamme, M Vang, S G Waley.   

Abstract

In Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens strains isolated from clinical specimens in the south of Sweden two variants of beta-lactamase were distinguished by isoelectric focusing (IEF). The BRO-1 (Ravasio type) enzyme was the most common in Branhamella catarrhalis, constituting about 90% of the beta-lactamase found in this species, while the BRO-2 enzyme (1908 type) was as common as BRO-1 in Moraxella nonliquefaciens. The determinants mediating the production of BRO-1 and BRO-2 were both transferable by conjugation. Cell-bound beta-lactamase from reference strains producing BRO-1 and BRO-2 could be solubilized by papain digestion. The isoelectric point of the solubilized enzymes differed distinctly between BRO-1 (pI 6.5) and BRO-2 (pI 6.9). The molecular species of BRO-1 and BRO-2 released by papain digestion were purified by affinity chromatography with phenylboronic acid agarose gel. They had identical molecular weights of approximately 28,000. Their kinetic constants were indistinguishable for a number of substrates and beta-lactamase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396750     DOI: 10.1007/bf01962070

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  37 in total

Review 1.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  Emergence and persistence of beta-lactamase-producing bacteria in the upper respiratory tract in children treated with beta-lactam antibiotics.

Authors:  I Eliasson; E Holst; S Mölstad; C Kamme
Journal:  Am J Med       Date:  1990-05-14       Impact factor: 4.965

3.  Novel beta-lactamase from Branhamella catarrhalis.

Authors:  A B Hoi-Dang; C Brive-Le Bouguenec; M Barthelemy; R Labia
Journal:  Ann Microbiol (Paris)       Date:  1978-10

4.  Kinetics of suicide substrates. Practical procedures for determining parameters.

Authors:  S G Waley
Journal:  Biochem J       Date:  1985-05-01       Impact factor: 3.857

5.  In vitro sensitivity to penicillin V and beta-lactamase production of Branhamella catarrhalis.

Authors:  B E Malmvall; J E Brorsson; J Johnsson
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

6.  Pathogenicity of and beta-lactamase production by Branhamella (Neisseria) catarrhalis.

Authors:  A Percival; J E Corkill; J Rowlands; R B Sykes
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

7.  Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases.

Authors:  A Philippon; J Y Riou; M Guibourdenche; F Sotolongo
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Bronchopulmonary infection due to B. catarrhalis. Clinical features and therapeutic response.

Authors:  D T McLeod; F Ahmad; M J Croughan; M A Calder
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Purification and some properties of streptococcal protein G, a novel IgG-binding reagent.

Authors:  L Björck; G Kronvall
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

10.  Upper respiratory tract infections. Ecological and therapeutic aspects of beta-lactamase production with special reference to Branhamella catarrhalis.

Authors:  I Eliasson; C Kamme
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more
  10 in total

1.  Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

Authors:  S S Richter; P L Winokur; A B Brueggemann; H K Huynh; P R Rhomberg; E M Wingert; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

3.  Residence of Streptococcus pneumoniae and Moraxella catarrhalis within polymicrobial biofilm promotes antibiotic resistance and bacterial persistence in vivo.

Authors:  Antonia C Perez; Bing Pang; Lauren B King; Li Tan; Kyle A Murrah; Jennifer L Reimche; John T Wren; Stephen H Richardson; Uma Ghandi; W Edward Swords
Journal:  Pathog Dis       Date:  2014-02-03       Impact factor: 3.166

4.  Moraxella (Branhamella) catarrhalis BRO beta-lactamase: a lipoprotein of gram-positive origin?

Authors:  H J Bootsma; P C Aerts; G Posthuma; T Harmsen; J Verhoef; H van Dijk; F R Mooi
Journal:  J Bacteriol       Date:  1999-08       Impact factor: 3.490

Review 5.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

6.  Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis.

Authors:  H J Bootsma; H van Dijk; J Verhoef; A Fleer; F R Mooi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 7.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

8.  Presumed endocarditis caused by BRO beta-lactamase-producing Moraxella lacunata in an infant with Fallot's tetrad.

Authors:  Noriyuki Nagano; Junichi Sato; Christophe Cordevant; Yukiko Nagano; Fumiaki Taguchi; Matsuhisa Inoue
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

9.  Challenges in identifying antibiotic resistance targets for point-of-care diagnostics in general practice.

Authors:  Konstantinos Mitsakakis; Wendy E Kaman; Gijs Elshout; Mara Specht; John P Hays
Journal:  Future Microbiol       Date:  2018-08-16       Impact factor: 3.165

10.  Moraxella nonliquefaciens bloodstream infection and sepsis in a pediatric cancer patient: case report and literature review.

Authors:  Carlos L Correa-Martínez; Kerstin K Rauwolf; Franziska Schuler; Miriam Füller; Stefanie Kampmeier; Andreas H Groll
Journal:  BMC Infect Dis       Date:  2019-10-11       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.